|
private:crystalgenomics
|
1537759
|
May 23rd, 2019 12:00AM
|
CrystalGenomics, Inc.
|
165
|
20.00
|
Open
|
Biotechnology
|
May 23rd, 2019 07:08PM
|
May 23rd, 2019 07:08PM
|
CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790).
CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate.
The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies.
By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.
|
Open
|
|
Open
|
CrystalGenomics, Inc., 5F Tower A, Korea Bio Park, 694-1, Sampyeong-Dong, Bundang-Gu
|
Seongnam-Si
|
Gyeonggi-Do
|
KR
|
463-400
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 17th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 16th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 15th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 14th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 13th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 12th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 11th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 10th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|
|
private:crystalgenomics
|
1537759
|
Feb 9th, 2018 12:00AM
|
CrystalGenomics, Inc.
|
131
|
23.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange.
Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders.
The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745).
|
|
|
|
|
|
|
|
|
|
CrystalGenomics
|
|
Health Care Equipment & Services
|